17 November 2017Americas

Texas universities sue J&J subsidiary over biodegradable fibres

A group of 14 educational institutions in Texas and biotech company TissueGen have sued a subsidiary of Johnson & Johnson for infringing two patents covering biodegradable fibres.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Educational institutions in cancer patent spat

5 April 2017 The Board of Regents of the University of Texas System and cancer research company Gensetix have filed a patent complaint against Baylor College of Medicine, Diakonos Research and an inventor called William Decker.

Biotechnology

Texas uni loses bid to shield cancer vaccine patents from IPRs

18 February 2021 The University of Texas has failed to persuade the US Court of Appeals for the Federal Circuit to review a ruling that prevented it from using sovereign immunity to protect its cancer vaccine patents from inter partes reviews.

More on this story

Educational institutions in cancer patent spat

5 April 2017 The Board of Regents of the University of Texas System and cancer research company Gensetix have filed a patent complaint against Baylor College of Medicine, Diakonos Research and an inventor called William Decker.

Biotechnology

Texas uni loses bid to shield cancer vaccine patents from IPRs

18 February 2021 The University of Texas has failed to persuade the US Court of Appeals for the Federal Circuit to review a ruling that prevented it from using sovereign immunity to protect its cancer vaccine patents from inter partes reviews.

More on this story

Educational institutions in cancer patent spat

5 April 2017 The Board of Regents of the University of Texas System and cancer research company Gensetix have filed a patent complaint against Baylor College of Medicine, Diakonos Research and an inventor called William Decker.

Biotechnology

Texas uni loses bid to shield cancer vaccine patents from IPRs

18 February 2021 The University of Texas has failed to persuade the US Court of Appeals for the Federal Circuit to review a ruling that prevented it from using sovereign immunity to protect its cancer vaccine patents from inter partes reviews.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York